Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 18/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 11/20 | 0.50 |
| ▸ | PDE4A | P27815 | 9/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.50 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843398 | 0.88 | PDE4B (0.45) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL2848137 | 0.87 | PDE3A (0.46) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL2847004 | 0.87 | PDE3A (0.49) | PDE4BPDE3APDE3B | |
| SCHEMBL2844867 | 0.87 | CHEK1 (0.45) | PDE4BPDE3APDE3B | |
| SCHEMBL184502 | 0.84 | PDE4B (0.61) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL183965 | 0.83 | PDE3A (0.50) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL184199 | 0.81 | PDE3A (0.43) | PDE4BPDE3APDE3BKDM4EMAPT | |
| SCHEMBL184769 | 0.81 | PDE4B (0.47) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL184573 | 0.81 | PDE4B (0.46) | PDE4BPDE3APDE4APDE4CPDE4D | |
| SCHEMBL184245 | 0.80 | PDE4B (0.50) | PDE4BPDE3APDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0126651-A2 | 2,4-Dihydro-5-((substituted)phenyl)-4,4-disubstituted-3H-pyrazol-3-ones, 2,4-dihydro-5-((substituted)phenyl)-4, 4-disubstituted-3H-pyrazol-3-thiones, and a process for producing the same | WARNER-LAMBERT COMPANY (US) | 1984-11-28 | — | — | EP | claimed |
| US-9340522-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2016-05-17 | — | — | US | disclosed |
| EP-2356103-B1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2015-08-26 | — | — | EP | disclosed |
| US-9090597-B2 | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| US-20140378509-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2014-12-25 | — | — | US | disclosed |
| US-8865745-B2 | Pyrazolone derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2014-10-21 | — | — | US | disclosed |
| US-20140073672-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | TAKEDA GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8609848-B2 | Pyrazolone-derivatives and their use as PDE-4 inhibitors | TAKEDA GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| EP-2402330-B1 | Pyrazolone-derivatives as PDE4 inhibitors | TAKEDA GMBH (DE) | 2013-06-26 | — | — | EP | disclosed |
| US-20130012544-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2013-01-10 | — | — | US | disclosed |
| EP-2508520-A1 | Pyrazolone-derivatives as PDE4 inhibitors | Nycomed GmbH (DE) | 2012-10-10 | — | — | EP | disclosed |
| EP-2402330-A1 | Pyrazolone-derivatives as PDE4 inhibitors | Nycomed GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| EP-2148876-B1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-28 | — | — | EP | disclosed |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | NYCOMED GMBH (DE) | 2011-09-08 | — | — | US | disclosed |
| EP-2356103-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | Nycomed GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010055083-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PD4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | NYCOMED GMBH (DE) | 2010-05-13 | — | — | US | disclosed |
| US-4661496-A | Cardiotonic and antihypertensive 2,4-dihydro-5-[(substituted)phenyl]-4,4-disubstituted-3H-pyrazol-3-ones | WARNER-LAMBERT COMPANY (US) | 1987-04-28 | — | — | US | disclosed |
| US-4550119-A | 2,4-Dihydro-5-[(substituted)phenyl]-4,4-disubstituted-3H-pyrazol-3-ones | WARNER-LAMBERT COMPANY (US) | 1985-10-29 | — | — | US | disclosed |
| EP-0126651-A2 | 2,4-Dihydro-5-((substituted)phenyl)-4,4-disubstituted-3H-pyrazol-3-ones, 2,4-dihydro-5-((substituted)phenyl)-4, 4-disubstituted-3H-pyrazol-3-thiones, and a process for producing the same | WARNER-LAMBERT COMPANY (US) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120757-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE3A | PDE4B 2/4885PDE3A 3/4885PDE4A 1/4885 |
| US-20130012544-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE5A | PDE4B 2/4885PDE3A 6/4885PDE4A 1/4885 |
| US-20110218201-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | PDE4B 4/4885PDE3A 3/4885PDE4A 1/4885 |
| US-20140378509-A1 | PYRAZOLONE DERIVATIVES AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4D | PDE4B 2/4885PDE3A 9/4885PDE4A 1/4885 |
| US-20140073672-A1 | NOVEL PYRAZOLONE-DERIVATIVES AND THEIR USE AS PDE-4 INHIBITORS | PDE4A, PDE3B, PDE3A | PDE4B 4/4885PDE3A 3/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.